To the Editor The JAMA Clinical Evidence Synopsis on zinc for the common cold by Drs Das and Singh 1 was a summary of their Cochrane review. 2 I noticed inconsistencies in the synopsis and so attempted to replicate their data.
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In Reply The findings reported in the JAMA Clinical Evidence Synopsis were based on randomized clinical trials, as was our Cochrane review. 1 The comparison of the 2 doses (≥75 mg/d vs <75 mg/d) of zinc was performed as a part of a network metaanalysis, which is a valid technique to assess the comparative effectiveness of interventions among similar study populations that have not been compared directly in randomized clinical trials. 2 The prerequisite of a network meta-analysis is that the trials should have used the same intervention in the same population and setting, for the same health problem, and measured the same outcome. We therefore selected trials using zinc lozenges that were conducted in the same country (United States), in the same setting (outpatient setting), in the same population (mostly adults), for the same health problem (naturally acquired cold), and for the same outcome (duration of cold). This analysis was not included in the Cochrane review.
We agree with Dr Hemilä's point that 3 of the 5 low-dose zinc trials had problems in the formulation of their zinc lozenges (were nonacetate lozenges) so that zinc was not released freely. However, similar kinds of formulations that released more and less ionic zinc were included in both lowdose and high-dose groups.
There are many possible analytic approaches in a metaanalysis, and we originally chose to triple count adverse event data for 1 study. 3 A more commonly used method is to combine all relevant intervention groups into a single group, and to combine all relevant control groups into a single control group. 4 We reanalyzed the data in this way and found a minimal but insignificant difference from the previous calculation (60.2% for lozenges vs 48.4% for placebo; number needed to harm [NNH], 9). The conclusion remains the same: "zinc lozenges were associated with a higher incidence of adverse events compared with placebo." This is consistent with findings from published clinical trials on zinc lozenges for the common cold. 5 Moreover, regarding the study in question, 3 the authors reported adverse events to be more common in the lozenges group (13%-19%; mean, 16%) than in the placebo group (10%).
We agree with Hemilä that the negative findings for the low-dose (<75 mg/d) zinc lozenge trials may be related to the low dose or problems in formulations, and the estimation of zinc lozenge effects should focus on trials using high doses (≥75 mg/d) of zinc.
